Cas:4343-75-3 4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione manufacturer & supplier

Chemical Name:4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione

CAS.NO:4343-75-3

Synonyms:4-amino-4H-1,2,4-triazole-3-thiol;3-mercapto-4-amino-4H-1,2,4-triazole;MFCD00128280;4-amino-3-mercapto-1,2,4-triazole;4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione;4-Amino-1,2,4-triazole-3-thiol;4-amino-3-mercapto-4h-1,2,4-triazole;3H-1,2,4-Triazole-3-thione, 4-amino-2,4-dihydro-;F0820-0343;4-amino-5-mercapto-1,2,4-triazole

Molecular Formula:C₂H₄N₄S

Molecular Weight:116.145

HS Code:2933990090

Physical and Chemical Properties:

Melting point:156-158

Boiling point:322.1±25.0 °C at 760 mmHg

Density:1.9±0.1 g/cm3

Index of Refraction:1.897

PSA:95.53000

Exact Mass:116.015663

LogP:-0.22

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-amino-4H-1,2,4-triazole-3-thiol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-amino-5-mercapto-1,2,4-triazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione Use and application,4-Amino-1,2,4-triazole-3-thiol technical grade,usp/ep/jp grade.

Related News: China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases. 4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione manufacturer A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643). 4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione supplier China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases. 4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione vendor AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 4-Amino-2,4-dihydro-3H-1,2,4-triazole-3-thione factory The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.